The executive order aims to cut US prescription drug costs by linking them to the lowest prices paid internationally.

Feldman and Schor explain that the patent dance is a complex process to determine which of a biologic manufacturer’s patents ...

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara ...

BENGALURU, India, April 28, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523) (NSE: BIOCON), today ...

Aurobindo Pharma subsidiary CuraTeQ Biologics’ biosimilar for breast cancer has been recommended for marketing authorisation by the Committee for Medicinal Products for Human Use of the European ...

Bengaluru-based Biocon Biologics Ltd (BBL), the biosimilars company and subsidiary of Biocon Ltd, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

This week, CuraTeQ Biologics (a wholly owned step-down subsidiary of Aurobindo Pharma Limited) announced that its trastuzumab biosimilar, DAZUBLYS, has received a positive opinion from the ...

Currently, 90% of biologics facing patent expiry over the next decade lack biosimilar candidates, limiting potential savings. By shortening development timelines, reducing research and development ...

Since their introduction within the past few decades, biosimilars outrivaled biologics in reducing treatment costs and improving access to therapies for chronic conditions such as cancer, rheumatoid ...

From the creation of a regulatory pathway for biosimilars in the EU only three biologics experienced EU biosimilar competition until the launch of Remsima/Inflectra in 2013, and none have (as at ...